ME/CFS Evidence Browser — Classified Studies on Myalgic Encephalomyelitis

141–160 of 1,185 studies

A placebo-controlled, double-blind, randomized controlled trial of a natural killer cell stimulant (BioBran MGN-3) in chronic fatigue syndrome.

McDermott, C, Richards, S C M, Thomas, P W et al.·QJM : monthly journal of the Association of Physicians·2006

This study tested whether a supplement called BioBran MGN-3 could reduce fatigue in people with ME/CFS by boosting immune cells called natural killer cells. Seventy-one patients took either the supplement or a placebo for 8 weeks. Both groups improved during the study, but the supplement group did not improve significantly more than the placebo group, suggesting the supplement itself was not the reason for improvement.

Evidence Atlas

Evidence browser

A placebo-controlled, double-blind, randomized controlled trial of a natural killer cell stimulant (BioBran MGN-3) in chronic fatigue syndrome.

Immune modulation with a staphylococcal preparation in fibromyalgia/chronic fatigue syndrome: relation between antibody levels and clinical improvement.

Treatment with staphylococcus toxoid in fibromyalgia/chronic fatigue syndrome--a randomised controlled trial.

Lymphocyte markers and natural killer cell activity in fibromyalgia syndrome: effects of low-dose, sublingual use of human interferon-alpha.

Intravenous immunoglobulin is ineffective in the treatment of patients with chronic fatigue syndrome.

Clinical improvement in chronic fatigue syndrome is not associated with lymphocyte subsets of function or activation.

Consequences of live poliovirus vaccine administration in chronic fatigue syndrome.

Double-blind placebo-controlled study of the efficacy of oral terfenadine in the treatment of chronic fatigue syndrome.

Lessons from a pilot study of transfer factor in chronic fatigue syndrome.

alpha-Interferon treatment of patients with chronic fatigue syndrome.

A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome.

Changes in the 2-5A synthetase/RNase L antiviral pathway in a controlled clinical trial with poly(I)-poly(C12U) in chronic fatigue syndrome.

Immunological and psychological dysfunction in patients receiving immunotherapy for chronic fatigue syndrome.

A controlled trial of intravenous immunoglobulin G in chronic fatigue syndrome.

A double-blind, placebo-controlled trial of intravenous immunoglobulin therapy in patients with chronic fatigue syndrome.

Charting the circulating proteome in ME/CFS using cross-system profiling to uncover mechanistic insights.

Urinary Peptidomic Profiling In Post-Acute Sequelae of SARS-CoV-2 Infection: A Case-Control Study.

Multi-omics identifies lipid accumulation in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome cell lines: a case-control study.

Chronic Reactivation of Persistent Human Herpesviruses EBV, HHV-6 and VZV and Heightened Anti-dUTPase IgG Antibodies Are a Recurrent Hallmark in Post-Infectious ME/CFS and is Associated With Fatigue.

Overlapping Clinical Presentation of Long COVID and Postacute COVID-19 Vaccination Syndrome: Phenotypes, Severity, and Biomarkers.

Curated Collections

Neuroinflammation Evidence

Metabolism & Mitochondria

Biomarkers

PEM-Specific Research